Physician profile
Ernest E Gilmore
NPI 1639143399
$1,899.56
in general payments reported to CMS, 2019-2025
17 companies · $431 in 2025
The $431 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $281 · 2023: $606 · 2024: $582 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,605 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,605.06 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $694.85 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Exact Sciences Corporation | $183.94 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $166.45 | 2022-2024 | Mounjaro |
| Novo Nordisk INC | $155.42 | 2022-2025 | Ozempic, Rybelsus |
| Dexcom, INC. | $109.67 | 2022-2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $108.67 | 2023-2025 | |
| Abbott Laboratories | $100.72 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $98.98 | 2023-2025 | |
| Amgen INC. | $59.32 | 2023-2025 | Otezla, Repatha, Evenity |
| Novartis Pharmaceuticals Corporation | $43.90 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $41.99 | 2022 | |
| Glaxosmithkline, LLC. | $40.55 | 2024 | Shingrix |
| Phathom Pharmaceuticals, INC. | $23.06 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $20.66 | 2022 | |
| Phadia US INC. | $19.94 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $16.08 | 2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.36 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernest Gilmore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.